CIK 0001339005 · <br>Emerging growth company
FEMASYS INC
Sign in to watch- Ticker
- FEMY
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 113713499
- Phone
- 770-500-3910
- Business address
- 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE, GA, 30024
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-28 | Currie Daniel Scott Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +29,184 | 29,184 | ||
| 2025-01-28 | Currie Daniel Scott Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +59,313 | 59,313 | ||
| 2025-01-28 | Currie Daniel Scott Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +140,700 | 140,700 | ||
| 2025-01-28 | Thomas Christine E Chief Reg & Clinical Officer | Grant or award · Stock Option (Right to Buy) | +55,090 | 55,090 | ||
| 2025-01-28 | Thomas Christine E Chief Reg & Clinical Officer | Grant or award · Stock Option (Right to Buy) | +28,682 | 28,682 | ||
| 2025-01-28 | Thomas Christine E Chief Reg & Clinical Officer | Grant or award · Stock Option (Right to Buy) | +23,600 | 23,600 | ||
| 2025-01-28 | Elefant Dov Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +72,045 | 72,045 | ||
| 2025-01-28 | Elefant Dov Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +114,300 | 114,300 | ||
| 2024-07-12 | Silverman Joshua Director | Grant or award · Stock Option (Right to Buy) | +17,600 | 17,600 | ||
| 2024-07-12 | Larsen Charles Director | Grant or award · Stock Option (Right to Buy) | +17,600 | 17,600 | ||
| 2024-07-12 | Milnes Alistair Director | Grant or award · Stock Option (Right to Buy) | +17,600 | 17,600 | ||
| 2024-07-12 | Uzialko Edward R Director | Grant or award · Stock Option (Right to Buy) | +17,600 | 17,600 | ||
| 2024-02-12 | Spector Richard D. Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2024-02-01 | Currie Daniel Scott Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +61,900 | 61,900 | ||
| 2024-02-01 | Elefant Dov Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +84,000 | 84,000 | ||
| 2024-02-01 | Thomas Christine E SVP, Regulatory & Clinical | Grant or award · Stock Option (Right to Buy) | +32,600 | 32,600 | ||
| 2024-02-01 | Lee-Sepsick Kathy Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +204,900 | 204,900 | ||
| 2023-11-21 | Silverman Joshua Director | Grant or award · Stock Option (Right to Buy) | +17,000 | 17,000 | ||
| 2023-10-10 | Thomas Christine E SVP, Regulatory & Clinical | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2023-07-03 | Elefant Dov Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +105,200 | 105,200 |
Page 4 of 7 · 127 trades